Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...  The number of retail health clinics in ... thanks to drug store chains, according to Kalorama Information.  ... downturn, retail clinic growth had been at a standstill, ... number of retail clinics reached nearly 1,600 according to ... Overview and 2014 Consumer Survey Results .  ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... , October 30, 2014 ... GG hilft beim Aufbau von Kuhmilchverträglichkeit     ... für Lebensmittelallergien bei Säuglingen und Kleinkindern. Der ... bei der Ernährung der Babys bzw. deren ... sich jedoch, dass sich bei einer beträchtlichen ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... Inc. (Nasdaq: REGN ) today announced that ... the U.S. Food and Drug Administration (FDA) for VEGF ... age-related macular degeneration (wet AMD).  Under the Prescription Drug ... review time from submission to FDA action is ten ...
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
Cached Medicine Technology:Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 2Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 3Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 4Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 5Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 6Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 7ResearchDx Launches Contract Diagnostics Organization (CDO) 2
(Date:10/30/2014)... Cary, N.C. (PRWEB) October 30, 2014 ... consumer-driven health care, is increasing efforts to help people ... out-of-pocket expenses continue to increase for prescription drugs in ... provides valuable savings and resources to bridge the relationship ... , One of the biggest challenges people face today ...
(Date:10/30/2014)... October 30, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... brain health. , The study, performed by the University ... 60 and 78 over a week-long period and observed ... daily physical activity. By examining the structural soundness of ...
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... -- When it comes to heart disease, a new study ... when they have symptoms that spell trouble. "The main ... a more severe or advanced stage of heart disease, there ... a Fulbright Scholar and research fellow at the Harvard School ... Heart and Stroke Foundation of Canada. In the study, ...
(Date:10/30/2014)... -- Eating a low-carb, high-fat diet could help control ... research. A review of five studies found ... on foods like bacon, eggs, heavy cream, butter, fish ... whose condition doesn,t improve with medication. "We need ... epilepsy whose seizures are not stopped by medications," study ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... S.C., June 2 Companion Data Services, ... International Organization for,Standardization (ISO) 9001:2000 certification, the ... CDS provides information technology and data processing ... by the federal,Centers for Medicare & Medicaid ...
... Work, Discusses Abbott,s, Contributions to Access, Innovation, Science ... June 2 Abbott (NYSE: ABT ),today ... Work,",which is available online at http://www.abbott.com/citizenship . ... innovation, science,education and the environment., Named to ...
... problem of how many identical-sized spheres can be randomly ... A team of physicists at The City College ... solution that could have implications for everything from processing ... May 29 edition of "Nature," they demonstrate that random ...
... Ignoring scientific,evidence of harm, the Louisiana State ... by the House, will require fluoride chemicals be,added ... to reduce,tooth decay. (The Advocate, 5/29/08), However, ... by,the prestigious National Research Council (NRC) reveals that ...
... Way for Approval of Merger, CHICAGO, June ... connectivity and information solutions that,physicians use to improve ... Hart-Scott-Rodino (HSR) Antitrust Improvements Act of,1976, with respect ... 2008,between Allscripts and Misys Healthcare to form Allscripts-Misys ...
... 15% of their daily calories, study finds , , MONDAY, June ... more sugary beverages and fruit juices than ever before, a ... now take in up to 15 percent of their total ... confirms previous research and suggests consumption is rising. , It,s ...
Cached Medicine News:Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 2Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 3Health News:Louisiana May Mandate Fluoridation Despite Evidence of Harm 2Health News:Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement 2Health News:Kids Gulping Down More Sugary Beverages 2Health News:Kids Gulping Down More Sugary Beverages 3
... for sample processing consists of a clear ... applied, a chemical-resistant polypropylene lid, and a ... handling. The manifold is designed for consistent ... samples simultaneously. Loading, washing, and elution steps ...
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
Replacement gaskets for the Empore 96 Well Vacuum Manifold Assembly, insure a tight seal....
... with hydrophobic PTFE membranes,Millex filter units ... for the sterilizing filtration of gases, ... for sterilizing or clarifying organic solutions. ... units are available with different outlet ...
Medicine Products: